NORTHVALE, N.J., Jan. 17, 2018 /PRNewswire/ -- ADM Tronics Unlimited, Inc. (ADMT), a technology-based developer and manufacturer of innovative technologies and products, today released the following investor update.
In 2013 ADMT management remodeled its business plan by implementing a strategy which would focus primarily on maximizing its "concept to quantity" engineering, regulatory and manufacturing division. The objective was to increase cash flow and reserves to internally fund the development of ADMT's proprietary medical technologies.
Although deploying the majority of its financial and human resources to this plan was laden with inherent risk, the strategy proved successful, providing increased profits in 17 of its last 18 quarters, eliminating debt and developing a cash reserve. This allowed the Company to follow-through on its strategic plan to shift a larger portion of its resources to advancing four of its own medical technology products in preparation for launch over the next year.
This was accomplished without any capital from outside sources. Strategic objectives were attained solely by the Company's own internal funding. Management believes ADMT is now positioned to become a leader in the medical technology industry.
Andre' DiMino, ADMT President stated, "We now have a series of "brand name" proprietary medical technologies we are preparing to bring to market over the next year."
Tinnitus Shield™, a patent-pending hearing technology to protect against damaging sounds known to cause tinnitus, (chronic ringing in the ears), common in the military, musicians, airline personnel, construction workers and a myriad of other occupations.
Aurex-3®, a patented, non-invasive therapeutic device for the treatment and control of tinnitus.
Alvio™, a respiratory therapy and training platform for patients who suffer from respiratory indications such as COPD, Asthma as well as for athletic training.
Sonotron®, a non-invasive therapeutic technology for treatment of pain such as associated with inflammatory joint conditions, ie osteoarthritis, tendinitis, bursitis, and TMJ. Management believes an effective, non-invasive pain modality can have an impact on overuse of opioids.
These technologies can serve large global markets, each ranging from $100 Million to over $1 Billion, the success of any one of which the Company believes can be a game-changer for its future.
Mark Brenner, President of Aurex International, Inc., the ADMT subsidiary that will market Tinnitus Shield and Aurex-3 stated "We received strong interest from potential distribution partners for the marketing and sale of our tinnitus technologies. We plan to launch Tinnitus Shield in the very near future as we prepare the Aurex-3 for submission to the FDA thereafter."
Mr. DiMino added "By delivering our own proprietary medical technologies to market we believe we can usher in an era of dramatic growth in revenues for ADMT. There is a very significant worldwide market for our technologies. This coming year marks the next generation of ADMT."
ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Medical Technologies; Eco-Friendly, Water-Based Formulations; and, Engineering, Regulatory and Manufacturing Services. The Company's headquarters, laboratories, and FDA-Registered medical device operations are in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for research, development and commercialization of diversified technologies. Additional information is available at admtronics.com.
Except for historical information contained herein, the matters set forth in this news release are "forward looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.